Pharmaceuticals & Biologics
To inquire about our available technologies, call our office (813) 745-6828
| Name & Description | Number |
|---|---|
| Small molecule: Cdk12 Inhibitors with Imidazole[1,2-A] Pyrazines | 24MA014N |
| Small molecule: Purine Covalent Based Cdk12 Inhibitors | 24MA013N |
| Small molecule: High Molecular Weight Polymers and Methods of Making the Same | 24MA001N |
| Small molecule: Processes For Synthesis of Trifunctionalized Sulfur (Vi) Compounds | 23MB036N |
| Small Molecule: Compounds For Targeted Degradation of Taf1 | 23MB027N |
| Small molecule: CA9 And CA12 Binding Molecules and Methods of Using the Same | 23MA017N |
| Small molecule: Helicase Inhibitors | 23MA012N |
| Small molecule: Imidazo[1,2-B] Pyridazine Inhibitors of Cyclin-Dependent Kinases | 22MB101N |
| Degrader: Degraders Of Son of Sevenless Homolog 1 | 22MB100N |
| Small Molecule: Inhibition Of Kir2Dl3 for the Enhancement of Adoptive Immunotherapy | 22MB099N |
| ULK3: ULK3 Inhibitors for the Treatment of Multiple Myeloma | 22MA087 |
| Immunomodulatory: Cereblon Degrading Molecules for the Treatment of Small Cell Lung Carcinoma and Melanoma | 22MA084 |
| Small molecule: Inhibitors Of Glutathione S-Transferase Zeta 1 (Gstz1) And Methods of Use | 22MA051N |
| Small molecule: Selective K-Ras Inhibitors for The Enhancement of Adoptive Immunotherapy | 22MA050N |
| Method: Methods Of Treating Ulk3-Associated Cancers | 22MA037N |
| Compound: CDRs For Glycosylated Acat1 | 22MA024N |
| Method: Synthesis Of Sulfur (Vi) Compounds and Reagents for Same | 22MA019N |
| Oligo: Downregulating Trolls Using Novel Antisense Oligonucleotides to Overcome Resistance to Chemotherapy | 22MA009N |
| Degrader: Helicase Degraders | 21MB079N |
| YAP1/OCT4: Small Molecule Inhibitors of the Protein Protein Interaction of YAP1 and OCT4 to Treat Cancer | 21MB072 |
| Prodrug: Prodrugs Of Temozolomide to Facilitate Delivery into Brain Tumor | 21MB068N |
| TAF1: Novel TAF1 PROTACS for the Treatment of Cancer | 21MB065N |
| Antibodies: Novel Targeted Nanobodies Against HPV E6/E7 to treat HPV Related Cancers | 21MA047N |
| Method: Combination Therapy of Polio Virus Receptor Inhibitors and Fucose | 21MA026N |
| p53: Combination Therapy of Hypothermia and Chemotherapy to Treat Temperature Sensitive p53 Mutant Tumors | 21MA021N |
| BRD4 JAK2: Sultam (cyclic sulfonamide) BRD4 JAK2 Inhibitors to Treat Myelofibrosis | 21MA020N |
| Small molecule: Novel JAK2 Inhibitor Piperadine Aniline Derivatives of Ruxolitinib to treat myelofibrosis | 21MA004N |
| Small molecule: Inhibitors Of Ulk1 and Methods of Use | 20MB060N |
| TROLLS: Inhibition Of TAp63 Regulated Oncogenic Long Noncoding RNAs (TROLLs) for the Treatment Of Cancer | 20MB056 |
| HPV E1: Novel Use for Aminocoumarins as HPV Helicase E1 Inhibitors to Treat Cancer | 20MB046 |
| CMG Helicase: Novel Replicative CMG Helicase Inhibitors (CMGi) to Treat Solid Tumors | 20MB046T2 |
| TAF1: Novel TAF1 Inhibitors for the Treatment of Cancer | 20MB037N |
| ACK1: Small molecule ACK1 Inhibitors for the Treatment of Castrate Resistant Prostate Cancer | 20MA015N |
| CDK12/CDK13: Novel Small Molecule Dual Inhibitors for CDK12/CDK13 for the Treatment of Triple Negative Breast Cancer | 19MB064N |
| Actinium Dotatate: Novel Atinum Dotatate Compounds with Low Toxicity and High Efficacy | 19MA018N |
| Method: Compositions and Methods for Treating Chronic Myelomonocytic Leukemia | 18MB079N |
| Method: Methods And Compositions Relating to a Novel Epidermal Growth Factor Receptor (EGFR) Splice Variant | 18MB071N |
| Novel BRD4/JAK2 Dual Inhibitor Cancer Therapeutics | 18MB053 |
| Ubiquitin Bispecific Antibody: Antibodies that Bring the E3 Ubiquitin Ligase into Close Proximity to Receptors to Induce the Receptor’s Degradation | 17MB056N |
| XBP-1: XBP-1 Inhibitor B-I09 for the Treatment of Acute GVHD and Solid Organ Rejection | 17MB051 |
| Method: Combination Therapies for the Treatment of Cancer | 17MB038N |